Alterations in serum thrombotic biomarker in patients with acute myocardial infarction
Poster Mar 24, 2015

Abdullah S. Alhomida
Background: Acute myocardial infarction (AMI) is a critical condition with a high rate of mortality and morbidity. There is a need of developing technologies for novel biomarkers or signatures discovery towards point-of-care testing for the management of AMI. The plasminogen activator system is an important defense mechanism against intravascular thrombosis. Tissue plasminogen activator (TPA) is a protein involved in the breakdown of blood clots by catalyzing the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. In a clotting situation, TPA is released from the storage pools in the endothelium and initiates fibrin breakdown. Plasminogen activator inhibitor-1 (PAI-1) functions as a principal inhibitor of TPA and hence counteracts fibrinolysis, the physiological process that degrades blood clots. The overall fibrinolytic activity is mainly determined by the balance between TPA and PAI-1 levels.
Aims: We compared the serum levels of TPA and PAI-1 in AMI patients versus healthy controls as well as a group of patients with dyslipidemia and high blood pressure risk group).
Results: Our results showed significantly higher levels of both TPA (5.2 ± 0.22 versus 2.5 ± 0.13 ng/mL) and PAI-1 (16.3 ± 0.24 versus 10.1 ± 0.17 ng/mL) in the sera of AMI patients as compared to controls whereas the risk group showed only non-significant increases.
Conclusion: A combination of these biomarkers could serve as a useful biomarker tool to assess the prognosis of AMI. (This study was supported by National Plan for Science and Technology Program by King Saud University Project Number 08-BIO571-02).
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

OTHER POSTERS
When there is a need to quickly analyze samples using a number of different PCR assays, it is likely that optimal conditions for each assay will not be the same. First, different assays often will require different annealing temperatures for their primers. In addition, amplicons may be designed to be of different lengths and therefore require varying durations of the extension step.
READ MORELike what you just read? You can find similar content on the communities below.
DiagnosticsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE